Bli medlem
Bli medlem

Du är här

2016-11-17

XBiotech Announces Research Collaboration with Renowned Gastroenterologist

nowned Gastroenterologist

XBiotech's True Human antibodies Targeting IL-1 alpha (IL-1?) to be used in
Researching Treatment for Inflammatory Bowel Disease (IBD)

AUSTIN, Texas, 2016-11-17 14:00 CET (GLOBE NEWSWIRE) --
XBiotech Inc. (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies,
announced today commencement of a collaboration with a research team at Case
Western Reserve University (CWRU) School of Medicine headed by leading
gastroenterologist, Fabio Cominelli, M.D., Ph.D. Dr. Cominelli and his research
team will conduct pre-clinical studies to help develop new treatments for
Inflammatory Bowel Disease (IBD) using the company’s pioneering approach to
using natural human antibody therapy to neutralize harmful inflammation. Dr.
Cominelli is a world-leading expert in inflammatory bowel disease. His group
was the first to report that specific blockade of interleukin-1 (IL-1) was
effective in reducing disease severity in colitis and that deregulated
inflammation is a cause of auto-inflammatory diseases, including IBD.

Dr. Cominelli is Chief of the Division of Gastroenterology and Liver Disease
and Director of the Digestive Health Institute at CWRU School of Medicine in
Cleveland and Chief Scientific Officer of the Digestive Health Institute at
University Hospitals Cleveland Medical Center. Dr. Cominelli is also the
Hermann Menges Jr. Chair in Internal Medicine and Professor at CWRU School of
Medicine. Dr. Cominelli has a professional interest in Crohn's disease,
gastrointestinal (GI) cancer, IBD and ulcerative colitis. He is a member of the
American Society for Clinical Investigation and Association of American
Physicians. He has previously earned a NIH Merit Award. His work has been
published in a number of peer-reviewed journals, such as Inflammatory Bowel
Diseases and The Journal of Immunology. Dr. Cominelli earned his medical degree
at Universita’ Degli Studi di Firenze in Florence, Italy, where he also
completed his internal medicine residency. He completed his gastroenterology
fellowship at Harbor-UCLA Medical Center in Torrance, California.

Dr. Cominelli stated, “I have researched IL-1’s role in disease severity in
colitis for many years, and am excited about the opportunity to be able to
selectively inhibit IL-1 alpha to better define its role in IBD. These results
will help shape the design of future clinical trials as we look for new and
better treatments for this wide-spread condition.”

John Simard, the Company’s President and Chief Executive Officer, commented,
“Dr. Cominelli’s past research has formed the foundation for clinical trials
with important implications for new treatments for patients suffering from
inflammatory diseases of the bowl. We are hopeful that this collaboration will
provide for further advances in treatment.”

About Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) is a common condition involving chronic
inflammation of the digestive tract. IBD primarily includes ulcerative colitis
and Crohn's disease, both of which are typically associated with severe
diarrhea, pain, fatigue and weight loss. IBD can have a devastating impact on
quality of life and in some cases lead to life-threatening complications. There
are approximately 1.6 million Americans and 5 million people worldwide
suffering from IBD with as many as 70,000 new cases diagnosed yearly in the
U.S1.

About True Human™ Therapeutic Antibodies
Unlike previous generations of antibody therapies, XBiotech’s True Human™
antibodies are derived without modification from individuals who possess
natural immunity to certain diseases. With discovery and clinical programs
across multiple disease areas, XBiotech’s True Human antibodies have the
potential to harness the body’s natural immunity to fight disease with
increased safety, efficacy and tolerability.

About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
pioneering the discovery, development and commercialization of therapeutic
antibodies based on its True Human™ proprietary technology. XBiotech currently
is advancing a robust pipeline of antibody therapies to redefine the standards
of care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the development of
innovative biotech manufacturing technologies designed to more rapidly,
cost-effectively and flexibly produce new therapies urgently needed by patients
worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations
regarding management's beliefs and expectations that involve substantial risks
and uncertainties. In some cases, you can identify forward-looking statements
by terminology such as "may," "will," "should," "would," "could," "expects,"
"plans," "contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or other
comparable terminology, although not all forward-looking statements contain
these identifying words. Forward-looking statements are subject to inherent
risks and uncertainties in predicting future results and conditions that could
cause the actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are subject to the
disclosures set forth in the "Risk Factors" section of certain of our SEC
filings. Forward-looking statements are not guarantees of future performance,
and our actual results of operations, financial condition and liquidity, and
the development of the industry in which we operate, may differ materially from
the forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak only as of
the date of this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information, future
events or otherwise, after the date of this press release.

1 The Facts About Inflammatory Bowel Disease. Crohn’s & Colitis Foundation of
America. November 2014.

Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.